GSK plc — Cyborg Score 7/10

Strategic Profile

Sales grew 5% to £7.6 billion in Q1 2026, with growth driven by Specialty Medicines up 14% and vaccines contributing through strong Shingrix sales. Shingrix delivered record quarterly sales of more than £1 billion, up 20%, with European sales up 51% following uptake in national immunization programs. The company is aggressively prosecuting clinical development with multiple ADC (antibody-drug conjugate) programs and MASH therapeutics in phase III trials.

Cyborg Score Rationale

GSK demonstrates solid operational momentum with specialty medicines and vaccine franchises driving double-digit growth in Q1 2026. Strong cash generation and aggressive pipeline prosecution position it well, though (April 2026) earnings miss indicates investor sentiment challenges.

Top Insights

• (Q1 2026) Specialty Medicines segment grew 14%, becoming primary growth driver alongside record Shingrix vaccine sales
• (Q1 2026) Core operating profit grew 10% with 110 basis point gross margin expansion despite EPS miss vs. analyst consensus
• Pipeline acceleration with seven Phase III trials started in 2025 and ten more starting in 2026, including ADC portfolio expansion
• (February 2024) Acquired Aiolos Bio for over $1 billion to strengthen asthma/immunology portfolio

Named Competitors

• Keytruda — PD-1 inhibitor for oncology
• Opdivo — PD-1/L1 inhibitor for cancer
• Gardasil — HPV vaccine competitor
• Polivy — ADC for B-cell lymphoma
• Ozempic — GLP-1 for metabolic disease

Recent Developments

• (April 29, 2026) Q1 2026 earnings: 5% sales growth, 10% core operating profit growth, but EPS miss of 46% vs. consensus
• (Q1 2026) Shingrix vaccine achieved record quarterly sales exceeding £1 billion, up 20% YoY
• (Q1 2026) ADC pipeline including ris-rez in small cell lung cancer and mo-rez in ovarian cancer showing encouraging anti-tumor activity
• (Q1 2026) MASH program with efimosfermin pivotal studies recruited and advancing on track

Open the full interactive GSK plc report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.